Perspective Therapeutics to Host In-Person and Virtual Analyst Day to Discuss Targeted Alpha-Particle Radiotherapy for Cancer on March 18, 2024
March 11 2024 - 8:00AM
Perspective Therapeutics, Inc. ("Perspective" or "the Company")
(NYSE AMERICAN: CATX), a radiopharmaceutical company that is
pioneering advanced treatment applications for cancers throughout
the body, today announced that it will host an in-person and
virtual analyst day at the New York Stock Exchange on Monday, March
18, 2024 at 10:00 AM ET. To register, click here.
The event will feature presentations from the following members
of the Company’s management:
- Thijs Spoor, Chief Executive Officer
- Michael K. Schultz, PhD, Chief Science Officer
- Markus Puhlman, MD, Chief Medical Officer
In addition, key opinion leader Richard L. Wahl, MD (Professor
of Radiology, Mallinckrodt Institute of Radiology at Washington
University School of Medicine) will provide an overview of the use
of specialized targeting peptides and personalized alpha-particle
radiopharmaceuticals such as 212Pb to diagnose tumors and deliver
powerful radiation specifically to cancer cells.
The event will highlight the Company's theranostic approach and
proprietary technology, including the development of complementary
imaging diagnostics that enable the ability to see the specific
tumor and then treat it, to potentially improve efficacy and
minimize toxicity associated with many other types of cancer
treatments. In addition, the Company’s management will discuss its
next radiotherapy compound in development and provide an overview
of its promising novel pretargeting technology.
A live question and answer session will follow the formal
presentations.
About Richard L. Wahl, MDRichard L. Wahl, MD,
is a professor at Mallinckrodt Institute of Radiology (MIR) at
Washington University School of Medicine in St. Louis and served as
the director of MIR from 2014 to 2023. An alumnus, Wahl completed a
diagnostic radiology residency and nuclear medicine fellowship at
MIR. Prior to being named director at MIR, he was director of the
Division of Nuclear Medicine at Johns Hopkins University and the
first recipient of the Henry N. Wagner Jr. Professorship.
Wahl is a leader in the use of PET scans to diagnose human
cancers and other diseases and was among the first to harness the
power of the immune system to precisely target radiation therapy to
cancers, a technique that has become known as radioimmunotherapy.
He has been at the forefront of efforts to combine quantitative
data from multiple kinds of scans to form so-called fusion images
that can help physicians more precisely diagnose and characterize
cancers.
Wahl has received numerous awards, including the 2018 Georg
Charles de Hevesy Award from the Society of Nuclear Medicine and
Molecular Imaging, where he served as president. He is an elected
member of the American Society for Clinical Investigation, the
American Association of Physicians and the National Academy of
Medicine. A fellow of the American College of Radiology, Wahl holds
18 radiology patents and has published more than 450 peer-reviewed
scientific manuscripts. He completed a research fellowship in
immunology and earned his medical degree from Washington University
in St. Louis.
About Perspective Therapeutics, Inc.Perspective
Therapeutics, Inc., is a radiopharmaceutical development company
that is pioneering advanced treatment applications for cancers
throughout the body. The Company has a proprietary technology that
utilizes the alpha emitting isotope 212Pb to deliver powerful
radiation specifically to cancer cells via specialized targeting
peptides. The Company is also developing complementary imaging
diagnostics that incorporate the same targeting peptides which
provide the opportunity to personalize treatment and optimize
patient outcomes. This "theranostic" approach enables the ability
to see the specific tumor and then treat it to potentially improve
efficacy and minimize toxicity associated with many other types of
cancer treatments.
The Company's melanoma (VMT01) and neuroendocrine tumor
(VMT-α-NET) programs have entered Phase 1/2a imaging and therapy
trials for the treatment of metastatic melanoma and neuroendocrine
tumors at several leading academic institutions. The Company has
also developed a proprietary 212Pb generator to secure key isotopes
for clinical trial and commercial operations.
For more information, please visit the Company's website at
www.perspectivetherapeutics.com.
Safe Harbor StatementThis press release
contains forward-looking statements within the meaning of the
United States Private Securities Litigation Reform Act of 1995.
Statements in this press release that are not statements of
historical fact are forward-looking statements. Words such as
"may," "will," "should," "expect," "plan," "anticipate," "could,"
"intend," "target," "project," "estimate," "believe," "predict,"
"potential" or "continue" or the negative of these terms or other
similar expressions are intended to identify forward-looking
statements, though not all forward-looking statements contain these
identifying words. Forward-looking statements in this press release
include statements concerning, among other things: the potential
use of specialized targeting peptides and personalized
alpha-particle radiopharmaceuticals such as 212Pb to diagnose
tumors and deliver powerful radiation specifically to cancer cells;
the Company’s belief that its next radiotherapy compound in
development has promising novel pretargeting technology; the
Company's prediction that complementary imaging diagnostics that
incorporate certain targeting peptides provide the opportunity to
personalize treatment and optimize patient outcomes; the Company's
expectation that its "theranostic" approach enables the ability to
see specific tumors and then treat them to potentially improve
efficacy and minimize toxicity associated with many other types of
cancer treatments; and other statements that are not historical
fact.
The Company may not actually achieve the plans, intentions or
expectations disclosed in the forward-looking statements and you
should not place undue reliance on the forward-looking statements.
These forward-looking statements involve risks and uncertainties
that could cause the Company's actual results to differ materially
from the results described in or implied by the forward-looking
statements, including, without limitation: the Company's ability to
continue as a going concern, the potential that regulatory
authorities may not grant or may delay approval for the Company's
product candidates; uncertainties and delays relating to the
design, enrollment, completion, and results of clinical trials;
unanticipated costs and expenses; early clinical trials may not be
indicative of the results in later clinical trials; clinical trial
results may not support regulatory approval or further development
in a specified indication or at all; actions or advice of
regulatory authorities may affect the design, initiation, timing,
continuation and/or progress of clinical trials or result in the
need for additional clinical trials; the Company's ability to
obtain and maintain regulatory approval for the Company's product
candidates; delays, interruptions or failures in the manufacture
and supply of the Company's product candidates; the size and growth
potential of the markets for the Company's product candidates, and
the Company's ability to service those markets; the Company's cash
and cash equivalents may not be sufficient to support its operating
plan for as long as anticipated; the Company's expectations,
projections and estimates regarding expenses, future revenue,
capital requirements, and the availability of and the need for
additional financing; the Company's ability to obtain additional
funding to support its clinical development programs; the
availability or potential availability of alternative products or
treatments for conditions targeted by the Company that could affect
the availability or commercial potential of its product candidates;
the ability of the Company to manage growth and successfully
integrate its businesses; the Company's ability to maintain its key
employees; whether there is sufficient training and use of the
Company's products and product candidates; the market acceptance
and recognition of the Company's products and product candidates;
the Company's ability to maintain and enforce its intellectual
property rights; the Company's ability to maintain its therapeutic
isotope supply agreement with the Department of Energy; the
Company's ability to continue to comply with the procedures and
regulatory requirements mandated by the FDA for additional trials,
Phase 1 and 2 approvals, FDA Fast Track approvals, and 510(k)
approval and reimbursement codes; and any changes in applicable
laws and regulations. Other factors that may cause the Company's
actual results to differ materially from those expressed or implied
in the forward-looking statements in this press release are
described under the heading "Risk Factors" in the Company's most
recent Transition Report on Form 10-KT and the Company's most
recent Quarterly Report on Form 10-Q, each filed with the
Securities and Exchange Commission (the "SEC"), in the Company's
other filings with the SEC, and in the Company's future reports to
be filed with the SEC and available at www.sec.gov. Forward-looking
statements contained in this news release are made as of this date.
Unless required to do so by law, we undertake no obligation to
publicly update or revise any forward-looking statements, whether
as a result of new information, future events, or otherwise.
Media and Investor Relations Contacts:
Russo Partners, LLC
Nic Johnson
nic.johnson@russopartnersllc.com
Adanna G. Alexander, Ph.D.
adanna.alexander@russopartnersllc.com
Harrison Seidner, Ph.D.
harrison.seidner@russopartnersllc.com
Perspective Therapeutics (AMEX:CATX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Perspective Therapeutics (AMEX:CATX)
Historical Stock Chart
From Apr 2023 to Apr 2024